Navigation Links
Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
Date:12/6/2007

ssure that the necessary audio applications are downloaded and installed. These programs can be obtained at no charge to the user.

A replay of the call will be available two hours after the completion of the call at (888) 286-8010 in the U.S., ((617) 801-6888 for international callers), pass code 74113063. The replay will be available through Monday, December 24, 2007.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with hematopoietic cell transplantion in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding t
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Casen Buswell has a rare ... to harden.  His case is one of only 14 known ... The only hospital in the United States ... offering treatment with the dual wave-length laser, is Methodist Children,s ... Antonio . Using a laser available in ...
(Date:9/18/2014)... Sept. 18, 2014 This BCC Research report discusses the ... players, market growth and size, and opportunities for different devices ... through 2018. Patent analysis in the report focuses on technological ... Europe and Japan ... and discuss the global medical device technologies market. - Analyze ...
(Date:9/18/2014)... and LONDON , ... era for biopharmaceutical companies. Competition for innovation, increasing ... to keep up with the fast-changing environment are ... influence clinical trials, and clinical trial costs continue ... patient recruitment. Studies conducted by industry ...
Breaking Medicine Technology:Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3
... Va., and BOSTON, Oct. 28 The final results of ... meeting of the American Association for the Study of Liver ... a combination therapy of peginterferon alfa-2a and ribavirin. It intended ... sustained viral response in genotype 1 patients with HCV who ...
... 28 Featuring the lowest dose and the fastest ... Flash dual-source computed tomography (CT) scanner is now poised ... to better serve its pediatric patients. The SOMATOM Definition ... that systems previously required to scan even the tiniest ...
Cached Medicine Technology:Difficult-to-Treat Patient Populations Respond Positively to Hepatitis C Treatment 2Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children 2Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children 3
(Date:9/18/2014)... 2014 Alexandria, VA — The ... 10 more communities have joined the growing ranks of ... accreditation. The decisions bring the number of governmental public ... is the non-profit organization that administers the national public ... the health of the public by advancing the quality ...
(Date:9/18/2014)... THURSDAY, Sept. 18, 2014 (HealthDay News) -- Exposure to ... a new study. Hearing different languages in ... and willing to learn from people who are different ... that children, like adults, are often biased against interacting ... them," said Amanda Woodward, a University of Chicago psychology ...
(Date:9/18/2014)... 2014 (HealthDay News) -- Older people become more physically ... the balance of stress hormones during bereavement changes with ... who are grieving are more likely to have weakened ... "During the difficult weeks and months after loss, we ... most abundant type of white blood cell and as ...
(Date:9/18/2014)... September 18, 2014 "Medical staff need ... while also maintaining the patient's privacy," said one of ... this idea in order to supply caregivers with the ... They created a prototype for The Helper to make ... staff to turn patient onto his or her side. ...
(Date:9/18/2014)... Luis Obispo, CA (PRWEB) September 18, 2014 ... Bootie introduced their newest, patent pending bunion splint to ... As one loyalist, Rosa, wrote: "I was absolutely delighted. It ... I honestly forget I am wearing them. THANK YOU FOR ... recently introduced design by saying, "The hole used to slip ...
Breaking Medicine News(10 mins):Health News:Ten More Communities Reaping Benefits of National Accreditation 2Health News:Ten More Communities Reaping Benefits of National Accreditation 3Health News:Ten More Communities Reaping Benefits of National Accreditation 4Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3
... release of the first long-range plan for tackling digestive ... each year. , Opportunities and Challenges in Digestive Diseases ... describes the impact of diseases ranging from foodborne infections ... for research over the next 10 years. The report ...
... BOTHELL, Wash., April 2 SCOLR Pharma, Inc. ... of HealthPro BioVentures LLC ("HealthPro"), a life sciences ... financial advisor in connection with the evaluation of ... strategic partners."We are excited about HealthPro joining our ...
... may work better than eating less, study finds , , THURSDAY, ... weight, cutting back on the calories in sugar-sweetened drinks, rather ... who found that cutting back on calories from sugary beverages ... nearly two-and-a-half pounds of lost weight over 18 months. ...
... Health Care has appointed a nationally recognized ... president of cancer services. (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b ... Children,s Research Hospital in Memphis, where he served ... domestic affiliates. Prior to that, he was chief ...
... Medical Systems (NYSE: VAR ) announced today that ... noon through 2 p.m. on May 7, 2009 in Boston ... Lafayette. Management presentations will cover financial performance through the ... opportunities in markets for oncology systems, x-ray imaging, and security ...
... Researchers at UT Southwestern Medical Center have shed ... process important information. , Researchers found in a study ... molecules used by nerve cells to communicate with one ... and changes brain-cell circuitry to process important information differently ...
Cached Medicine News:Health News:NIH releases the first research plan to reduce the burden of digestive diseases 2Health News:NIH releases the first research plan to reduce the burden of digestive diseases 3Health News:SCOLR Pharma, Inc. Announces Engagement of HealthPro as Financial Advisor 2Health News:Fewer Sugary Drinks Key to Weight Loss 2Health News:Fewer Sugary Drinks Key to Weight Loss 3Health News:Nationally Recognized Oncologist to Lead Aurora Health Care's Cancer Services 2Health News:Nationally Recognized Oncologist to Lead Aurora Health Care's Cancer Services 3Health News:Varian Medical Systems Schedules Mid-Year Review With Investors in Boston 2Health News:UT Southwestern researchers reveal how the brain processes important information 2
... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: